ARROWHEAD PHARMACEUTICALS IN's ticker is ARWR and the CUSIP is 04280A100. A total of 254 filers reported holding ARROWHEAD PHARMACEUTICALS IN in Q3 2023. The put-call ratio across all filers is 0.72 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $291,762,925 | -25.4% | 10,858,315 | -1.0% | 0.01% | -22.2% |
| Q2 2023 | $391,251,892 | +44.1% | 10,971,730 | +2.7% | 0.01% | +28.6% |
| Q1 2023 | $271,471,923 | -34.9% | 10,687,871 | +3.9% | 0.01% | -36.4% |
| Q4 2022 | $417,207,136 | +24.4% | 10,286,172 | +1.4% | 0.01% | +10.0% |
| Q3 2022 | $335,325,000 | -5.4% | 10,145,990 | +0.8% | 0.01% | 0.0% |
| Q2 2022 | $354,541,000 | -20.7% | 10,069,337 | +3.6% | 0.01% | -9.1% |
| Q1 2022 | $446,943,000 | -30.1% | 9,718,250 | +0.8% | 0.01% | -26.7% |
| Q4 2021 | $639,142,000 | +6.2% | 9,640,143 | -0.0% | 0.02% | 0.0% |
| Q3 2021 | $602,069,000 | -24.6% | 9,643,916 | +0.1% | 0.02% | -25.0% |
| Q2 2021 | $798,307,000 | +25.4% | 9,639,064 | +0.4% | 0.02% | +17.6% |
| Q1 2021 | $636,652,000 | -10.6% | 9,601,137 | +3.4% | 0.02% | -19.0% |
| Q4 2020 | $712,174,000 | +81.3% | 9,281,551 | +1.8% | 0.02% | +61.5% |
| Q3 2020 | $392,745,000 | -6.4% | 9,120,882 | -6.2% | 0.01% | -13.3% |
| Q2 2020 | $419,779,000 | +51.5% | 9,719,363 | +0.9% | 0.02% | +25.0% |
| Q1 2020 | $277,013,000 | -55.4% | 9,628,526 | -1.7% | 0.01% | -42.9% |
| Q4 2019 | $621,455,000 | +103.4% | 9,797,507 | -9.7% | 0.02% | +90.9% |
| Q3 2019 | $305,600,000 | +33.5% | 10,844,571 | +25.5% | 0.01% | +22.2% |
| Q2 2019 | $228,903,000 | +153.3% | 8,637,838 | +75.4% | 0.01% | +125.0% |
| Q1 2019 | $90,382,000 | +78.7% | 4,925,446 | +20.9% | 0.00% | +100.0% |
| Q4 2018 | $50,584,000 | -33.2% | 4,072,718 | +3.1% | 0.00% | -33.3% |
| Q3 2018 | $75,748,000 | +41.3% | 3,951,381 | +0.3% | 0.00% | +50.0% |
| Q2 2018 | $53,599,000 | +116.5% | 3,941,108 | +14.8% | 0.00% | +100.0% |
| Q1 2018 | $24,760,000 | +134.2% | 3,434,112 | +19.6% | 0.00% | – |
| Q4 2017 | $10,570,000 | -15.6% | 2,872,472 | -0.7% | 0.00% | -100.0% |
| Q3 2017 | $12,524,000 | +184.9% | 2,892,265 | +6.6% | 0.00% | – |
| Q2 2017 | $4,396,000 | -24.9% | 2,713,589 | -14.3% | 0.00% | – |
| Q1 2017 | $5,857,000 | +35.4% | 3,165,579 | +13.4% | 0.00% | – |
| Q4 2016 | $4,326,000 | -76.3% | 2,791,071 | +12.4% | 0.00% | -100.0% |
| Q3 2016 | $18,252,000 | +40.2% | 2,483,209 | +1.5% | 0.00% | 0.0% |
| Q2 2016 | $13,015,000 | – | 2,446,346 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| WESTERN FINANCIAL Corp | 820,264 | $54,392,000 | 33.22% |
| Johnson & Johnson Innovation - JJDC, Inc. | 3,260,869 | $216,228,000 | 28.00% |
| L1 Capital Pty Ltd | 296,024 | $19,629,000 | 4.93% |
| Aquilo Capital Management, LLC | 407,926 | $27,050,000 | 4.89% |
| Evolutionary Tree Capital Management, LLC | 72,948 | $4,837,000 | 2.86% |
| ACUTA CAPITAL PARTNERS, LLC | 108,000 | $7,161,000 | 2.58% |
| First Light Asset Management, LLC | 536,836 | $35,598,000 | 2.36% |
| Parkman Healthcare Partners LLC | 70,089 | $4,648,000 | 1.08% |
| Hood River Capital Management LLC | 357,082 | $23,678,000 | 0.76% |
| Vanguard Capital Wealth Advisors | 11,099 | $703,565,000 | 0.60% |